CD274 and cancer: Pembrolizumab (Keytruda®), an anti-PD-1 antibody, is a clinically used antibody designed to reinvigorate cytotoxic CD8+ T-cell responses by blocking the interaction between PD-L1/2 and PD-1, enabling CD8+ T-cells cells to recognize and kill cancer cells.